Bleeding risk from blood thinners in people with cancer
Official title: Prediction of Anticoagulant-Related Bleeding Risk in Patients with Cancer
Funded at Washington University · NIH-11237616 · Data updated 2026-11-12
This project will build a tool to predict how likely people with cancer are to have serious bleeding while taking blood thinners.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | January 5, 2023 |
| Project end | November 30, 2026 |
| Funding year | 2026 |
| Award (this year) | $389,391 |
| NIH project number | 5R01HL166386-04 |
| Project ID | NIH-11237616 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with cancer who have had a venous blood clot (VTE) or who are being considered for anticoagulant therapy to prevent or treat clots are the ideal candidates.
✕Less likely to help
People without cancer, those not taking anticoagulants, or patients whose bleeding risk is already clearly determined may not receive direct benefit from this work.
What this research studies
You would be part of work to create a prediction tool that estimates your chance of a major bleed while on anticoagulant therapy. The team will use medical records and clinical trial data from people with cancer and blood clots, and examine factors like cancer type, treatments, and the specific blood thinner used. They will develop and then calibrate the model especially for cancer patients who are at high risk of clotting and are being considered for preventive therapy. The end product would be a calculator clinicians can use to help balance preventing clots against the risk of dangerous bleeding for each person.
Why it matters
Potential benefit: If successful, this could help doctors personalize blood-thinner use to reduce dangerous bleeds while still preventing clots.
How similar studies have gone: Bleeding-risk models exist and perform in non-cancer populations, and recent trials support some direct oral anticoagulants in cancer, but a validated cancer-specific bleeding prediction tool is novel and untested.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Sanfilippo, Kristen Marie — Washington University
- Study coordinator: Sanfilippo, Kristen Marie
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.